AMGN stock forecast, quote, news & analysis

Key Takeaways

• Amgen shares rose approximately 2.9% over the last 30 days, closing at $385.16 on July 31, 2026, outpacing the broader market during a period of sector rotation.
• The stock has gained roughly 18.4% year-to-date, driven by strong commercial execution, an advancing pipeline, and resilient demand for key growth products like Repatha and Tezspire.
• Q2 2026 earnings are scheduled for release on August 4 after market close, with consensus estimates calling for EPS of $5.60 on revenue of $9.45 billion.
• A newly disclosed cybersecurity incident involving third-party cloud systems and a $74 million shareholder lawsuit settlement added complexity to the stock's narrative in late July.
• Amgen's experimental monthly obesity drug MariTide, now in six Phase 3 trials, remains a closely watched catalyst with potential to reshape long-term growth expectations.
• Wall Street maintains a consensus "Hold" rating with an average price target of $357, suggesting the stock is trading above most analysts' valuations heading into earnings.

Current Market Snapshot

Amgen shares have exhibited notable resilience through July 2026, advancing from $374.15 at the start of the month to $385.16 by July 31 — a gain of roughly 2.9%. The stock briefly dipped to an intra-month low of $353.95 on July 15 before staging a sharp recovery that pushed prices as high as $398.00 intraday on July 28, just shy of the 52-week high. Trading volume spiked during the rally, with nearly 2 million shares changing hands on July 28, reflecting heightened investor attention ahead of the company's second-quarter earnings report. With a beta of 0.41, Amgen has historically exhibited lower volatility than the broader market, yet the stock's 18.4% year-to-date gain substantially exceeds both the pharmaceutical industry average and the S&P 500.

Amgen (AMGN) Business Overview and Competitive Position

Amgen Inc., headquartered in Thousand Oaks, California, is one of the world's largest independent biotechnology companies, with a market capitalization of approximately $209 billion. Founded in 1980, the company discovers, develops, manufactures, and markets biologic medicines targeting serious illnesses across oncology, cardiovascular disease, inflammation, bone health, and neuroscience. Its commercial portfolio includes blockbuster therapies such as Prolia and Xgeva (osteoporosis and bone complications), Repatha (cardiovascular risk reduction), Otezla (psoriasis and psoriatic arthritis), Enbrel (inflammatory diseases), and Tezspire (severe asthma). The company is navigating a critical patent cliff, as Prolia and Xgeva lost U.S. exclusivity in February 2025, yet Amgen's newer growth drivers — including Repatha, Tezspire, Uplizna, Evenity, Imdelltra, and its biosimilar portfolio — are collectively offsetting much of the legacy erosion. Amgen also offers investors a reliable dividend, recently declaring a $2.52 per share quarterly payout, translating to a 2.6% annualized yield.

Recent Developments Driving AMGN

Several material events shaped Amgen's stock performance and investor sentiment during the trailing 30-day period. On the regulatory front, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting broader use of Repatha in high-risk adults without a prior heart attack or stroke, potentially expanding the drug's addressable market in Europe pending final approval. The company also declared its third-quarter 2026 dividend of $2.52 per share, reinforcing confidence in cash generation.

On the pipeline front, attention remains focused on MariTide (maridebart cafraglutide), Amgen's investigational monthly GIPR/GLP-1 receptor agonist for obesity, which has six Phase 3 trials underway. While the program carries substantial upside potential in the rapidly growing weight-loss market, it faces formidable competition from established leaders Eli Lilly and Novo Nordisk.

Less favorably, Amgen disclosed on July 31 that proprietary data and protected patient health information were exfiltrated from a cloud environment hosted by a third-party provider, triggering a cybersecurity investigation. The company stated it does not currently believe the incident will materially impact financial results. Separately, Amgen reached a $74 million preliminary settlement of a shareholder class-action lawsuit alleging the company delayed disclosing a potential $10.7 billion IRS tax liability related to transfer pricing practices between 2010 and 2015.

On Wall Street, analyst sentiment remained mixed. BMO Capital Markets maintained an Outperform rating with a $400 price target, while Barclays raised its target to $360 with an Equal Weight rating. Morgan Stanley cut its target to $333, and Citigroup held at $345 with a Hold rating. The consensus price target of approximately $357 sits below the stock's recent trading levels, reflecting caution around valuation and the ongoing denosumab biosimilar erosion.

Trending AI Robots

In an environment where biotech stocks can shift rapidly on clinical data, regulatory decisions, and earnings surprises, many traders turn to data-driven tools for systematic market analysis. Tickeron's Trending AI Robots page curates a select group of top-performing AI trading bots from a universe of hundreds that collectively trade thousands of tickers. Each bot is designed with a distinct strategy, time horizon, and performance profile — ranging from short-term swing trading to longer-term trend-following approaches — allowing users to identify AI-driven signals that align with their own trading style and risk tolerance. The curated section highlights only the most relevant and consistently performing bots, offering a streamlined entry point for those interested in exploring algorithmic trading in the biotech space and beyond.

2026 Outlook and What Investors Should Watch

Looking ahead, the immediate catalyst for AMGN is the second-quarter earnings report on August 4. Analysts expect $5.60 in EPS on $9.45 billion in revenue, with particular focus on volume trends for Repatha, Tezspire, and the company's biosimilar portfolio, as well as the pace of Prolia and Xgeva sales erosion. Amgen raised its full-year 2026 guidance earlier this year to $37.1–$38.5 billion in total revenue and non-GAAP EPS of $21.70–$23.10, and any revisions to that outlook will be closely scrutinized.

Beyond earnings, MariTide's Phase 3 progress represents the most significant longer-term value driver. Positive data could fundamentally reset Amgen's growth trajectory, while disappointing results would likely pressure the stock given the competitive landscape in obesity. Additional pipeline assets, including olpasiran for cardiovascular disease and Imdelltra in small-cell lung cancer, also warrant attention. On the risk side, the IRS tax case covering 2016–2018 remains unresolved, and the cybersecurity incident's full scope is still under investigation. With institutional ownership at 76.5% and the stock trading near its 52-week high, positioning and sentiment shifts around these catalysts will likely dictate AMGN's next major move.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations